Market Performance - The Hainan Free Trade Zone concept index declined by 1.76%, ranking among the top declines in concept sectors as of July 28 [1] - Within the sector, companies such as Caesar Travel, Hainan Development, and Hainan Ruize experienced significant declines, while a few stocks like *ST Yedao, Kangzhi Pharmaceutical, and *ST Shuangcheng saw increases of 4.49%, 4.34%, and 1.56% respectively [1] Capital Flow - The Hainan Free Trade Zone concept saw a net outflow of 724 million yuan from major funds today, with 20 stocks experiencing net outflows, and 5 stocks seeing outflows exceeding 50 million yuan [2] - The stock with the highest net outflow was Caesar Travel, with a net outflow of 188 million yuan, followed by HNA Holding and Hainan Ruize with outflows of 132 million yuan and 75 million yuan respectively [2] Stock Performance - The top stocks with net outflows in the Hainan Free Trade Zone concept included: - Caesar Travel: -7.05% with a turnover rate of 21.89% and a net outflow of 187.57 million yuan - HNA Holding: -3.75% with a turnover rate of 2.54% and a net outflow of 132.31 million yuan - Hainan Ruize: -5.62% with a turnover rate of 13.04% and a net outflow of 75.27 million yuan [3]

Group 1 - The company expects a net loss attributable to shareholders in the range of 13 million to 19 million yuan for the current reporting period, compared to a loss of 16.9462 million yuan in the same period last year, indicating a potential decrease of 12.12% to an increase of 23.29% [1] - The expected operating income for the current period is projected to be between 75 million and 95 million yuan, down from 94.8926 million yuan in the previous year [1] - The company attributes the performance changes to significant price reductions in key products due to market reforms and competitive bidding, particularly affecting domestic sales profits [2] Group 2 - The company has received FDA approval for the abbreviated new drug application (ANDA) for injectable paclitaxel (albumin-bound), which has begun to generate export sales, contributing positively to export profits [2] - Non-recurring gains are expected to contribute approximately 2.55 million yuan to net profit, primarily from government subsidies and investment income [2] - The company is actively taking measures to address the delisting risk warning imposed by the Shenzhen Stock Exchange due to financial performance concerns [3]

Meeting Announcement - The company will hold its first extraordinary general meeting of shareholders in 2025 on July 31, 2025 [1] - The meeting will be conducted in accordance with legal and regulatory requirements [1] Voting Procedures - Shareholders can vote through the Shenzhen Stock Exchange trading system and the internet voting system on July 31, 2025 [6][7] - Specific voting times are set for the trading system from 9:15-9:25, 9:30-11:30, and 13:00-15:00 [1] - Shareholders must choose either on-site or online voting, with the first vote counted in case of duplicates [1][6] Attendance and Registration - All shareholders registered by July 25, 2025, at 15:00 are entitled to attend the meeting [2] - Registration methods include in-person attendance with valid identification or proxy representation [3][4] - Remote shareholders can register via mail, email, or fax by July 29, 2025 [4] Meeting Agenda - The meeting will review non-cumulative voting proposals [2][5] - Shareholders can appoint proxies who do not need to be company shareholders [2][3] Contact Information - For inquiries, shareholders can contact Ms. Yu Xiaofeng or Ms. Li Fen via provided email and phone [6]

Overview - The company, Hainan Shuangcheng Pharmaceutical Co., Ltd., is providing a guarantee for its subsidiary, Ningbo Shuangcheng Pharmaceutical Co., Ltd., to secure a loan of 40 million yuan from China Construction Bank [1][2]. Guarantee Details - The loan is needed for daily operations and has a term until July 31, 2028 [1]. - The company and its controlling shareholder, Shuangcheng Investment Co., Ltd., will provide joint liability guarantees for the loan [1][2]. - The guarantee period will last for three years after the main contract's debt fulfillment [1]. Financial Status - Ningbo Shuangcheng has a net asset value of 69.0791 million yuan and reported a net profit loss of 57.3425 million yuan [2]. - The total assets of Ningbo Shuangcheng are 338.6156 million yuan, with total liabilities of 296.7085 million yuan [3]. Impact on the Company - The board believes that the guarantee will support Ningbo Shuangcheng's funding needs and promote its business development [4]. - The company asserts that the guarantee does not harm the interests of the company or its shareholders and will not affect its independence [4][5]. Board and Independent Directors' Opinions - The board has approved the guarantee, stating it aligns with internal control systems and legal regulations [4][5]. - Independent directors unanimously support the guarantee, emphasizing its necessity for Ningbo Shuangcheng's operations and compliance with regulations [5]. Related Transactions - The total amount of related transactions with the controlling shareholder since the beginning of the year is 14.9383 million yuan, excluding the current transaction [5]. - After this guarantee, the total external guarantee amount by the company and its subsidiaries will be 165 million yuan, which does not exceed 41.94% of the company's latest audited net assets [5].

Group 1 - The board of directors of Hainan Shuangcheng Pharmaceutical Co., Ltd. held its 19th meeting of the 5th session on July 14, 2025, with all 6 directors present and participating in the voting [1] - The board approved a proposal to provide guarantees for its subsidiary, Ningbo Shuangcheng Pharmaceutical Co., Ltd., with a voting result of 3 in favor, 3 abstentions, and no opposition [2] - The board believes that providing guarantees will help the subsidiary secure funding and promote its business development, while the controlling shareholder will provide a guarantee of the same amount, ensuring manageable risk [2] Group 2 - The proposal for the guarantee will be submitted to the shareholders' meeting for approval, with related shareholders required to abstain from voting [2] - The board also approved a proposal to convene the first temporary shareholders' meeting of 2025, with a unanimous voting result of 6 in favor [2]

证券代码：002693 证券简称：*ST双成 公告编号：2025-045 海南双成药业股份有限公司 关于为控股子公司提供担保暨关联交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别风险提示： 公司本次提供担保的对象为合并报表范围内的控股子公司，其最近一期经审 计的资产负债率超过 70%，但其经营状况良好，公司能够全面掌控其运行，担保 风险可控。特此提醒投资者充分关注担保风险。 一、担保情况概述 海南双成药业股份有限公司（以下简称"公司"）控股子公司宁波双成药业 有限公司（以下简称"宁波双成"）因日常经营需要，拟向中国建设银行股份有 限公司宁波杭州湾新区支行（以下简称"建设银行"）申请 4,000 万元借款，借 款期限至 2028 年 7 月 31 日。公司和公司控股股东海南双成投资有限公司（以下 简称"双成投资"）拟为宁波双成向建设银行借款分别提供连带责任担保，担保 期限为主合同下的债务履行期届满之日起三年。 双成投资为公司控股股东，同时持有宁波双成 48.81%的股份。根据《深圳 证券交易所股票上市规则》等相关规定，本次对外提供担保构成关联交易 ...

[Performance Forecast and Financial Indicators](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E8%AE%A1%E6%83%85%E5%86%B5) The company anticipates continued losses in the first half of 2025, with net profit attributable to shareholders projected to be a loss of 13 million to 19 million yuan, while operating revenue is expected to decline year-over-year to a range of 75 million to 95 million yuan Performance Forecast Summary | Item | Current Period (2025 H1 Forecast) | Prior Period (2024 H1) | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders of Listed Company (Million Yuan)** | Loss: 13 – 19 | Loss: 16.9462 | | **Year-over-Year Change** | Profit Decrease 12.12% to Profit Increase 23.29% | - | | **Net Profit After Deducting Non-recurring Gains and Losses (Million Yuan)** | Loss: 15.55 – 21.55 | Loss: 17.7595 | | **Basic Earnings Per Share (Yuan/Share)** | Loss: 0.0313 – 0.0458 | Loss: 0.0409 | | **Operating Revenue (Million Yuan)** | 75 – 95 | 94.8926 | | **Operating Revenue After Deduction (Million Yuan)** | 72 – 92 | 92.5754 | [Operating Performance and Attribution](index=1&type=section&id=%E4%B8%89%E3%80%81%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8A%A8%E5%8E%9F%E5%9B%A0%E8%AF%B4%E6%98%8E) The company's overall performance remained relatively stable due to mixed results from domestic and international operations, with domestic profit decline offset by international sales growth and a positive impact from non-recurring gains - Domestic business profit declined due to the centralized drug procurement policy, leading to decreased sales of non-winning bids and significant price reductions for winning bids like Thymosin Alpha 1 for Injection, reducing domestic sales profit[4](index=4&type=chunk) - Export business profit increased as Paclitaxel (Albumin-bound) for Injection received US FDA approval in May 2025 and began export sales, alongside growth in Bivalirudin for Injection export revenue[4](index=4&type=chunk)[5](index=5&type=chunk) - Non-recurring gains and losses contributed approximately **2.55 million yuan**, primarily from government subsidies and investment income[5](index=5&type=chunk) [Important Notes and Risk Factors](index=1&type=section&id=%E5%9B%9B%E3%80%81%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA%E5%8F%8A%E5%85%B6%E4%BB%96%E7%9B%B8%E5%85%B3%E8%AF%B4%E6%98%8E) The company faces severe delisting risks due to its 2024 financial performance, with its stock already under *ST warning, and potential termination of listing if 2025 performance fails to meet standards, noting that this preliminary forecast is unaudited - The company's stock faces delisting risk as it was placed under a delisting risk warning (*ST) from April 30, 2025, due to negative audited net profit and operating revenue after deduction below **300 million yuan** in 2024[6](index=6&type=chunk) - Failure to meet performance standards in 2025 could trigger Article 9.3.12 of the Shenzhen Stock Exchange Listing Rules, leading to the termination of the company's stock listing[6](index=6&type=chunk) - This performance forecast is a preliminary estimation by the company's finance department and has not been audited by an accounting firm, thus subject to uncertainty[3](index=3&type=chunk)[6](index=6&type=chunk)

Core Viewpoint - *ST Shuangcheng (002693.SZ) expects a net loss of 13 million to 19 million yuan for the first half of 2025, compared to a loss of 16.9462 million yuan in the same period last year [1] Company Summary - The company attributes the expected loss to significant changes in market supply and pricing due to ongoing reforms in the pharmaceutical industry, with a notable decline in sales volume for non-winning bid products and a substantial drop in prices for winning bid products [1] - The company's main product, Thymosin Alpha 1 injection, experienced a price reduction during the new bidding period, leading to decreased domestic sales profits [1] - However, the company achieved a milestone with the approval of the abbreviated new drug application (ANDA) for Paclitaxel Injection (albumin-bound) by the U.S. Food and Drug Administration (FDA) in May 2025, which has begun to generate export sales [1] - Additionally, there was an increase in export revenue from the injection of Bivalirudin, contributing to improved export profits [1] - Overall, these factors resulted in minimal changes to the company's overall performance [1]

证券代码：002693 证券简称：*ST双成 公告编号：2025-046 海南双成药业股份有限公司 关于召开2025年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 海南双成药业股份有限公司（以下简称"公司"）第五届董事会第十九次会 议于 2025 年 7 月 14 日召开，会议定于 2025 年 7 月 31 日（星期四）召开 2025 年第一次临时股东会，现将本次股东会的有关事项通知如下： 一、召开会议的基本情况 1、股东会届次：2025 年第一次临时股东会 2、会议召集人：公司董事会 3、会议召开的合法、合规性：公司第五届董事会第十九次会议审议通过后， 决定召开股东会，本次股东会的召集程序符合法律、法规、规范性文件和《公司 章程》的规定。 4、现场会议召开时间：2025 年 7 月 31 日（星期四）下午 14：30 网络投票时间：2025 年 7 月 31 日 （1）通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 7 月 31 日 9:15-9:25，9:30-11:30 和 13:00-15:00； （2）通 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 海南双成药业股份有限公司（以下简称"公司"）第五届董事会第十九次会 议通知于 2025 年 7 月 11 日以书面送达或电子邮件等方式发出，并于 2025 年 7 月 14 日 10:00 以现场结合通讯表决的方式召开。会议应出席董事 6 人，实际参 加表决的董事 6 人。董事会秘书于晓风女士列席了会议。本次会议由董事长王成 栋先生主持，会议的召开符合有关法律法规、公司章程的规定。 二、董事会会议审议情况 （一）审议通过了《关于为控股子公司提供担保暨关联交易的议案》 证券代码：002693 证券简称：*ST双成 公告编号：2025-044 海南双成药业股份有限公司 第五届董事会第十九次会议决议公告 表决情况：同意 3 票，回避 3 票，反对 0 票，弃权 0 票。 公司董事会认为，公司通过提供担保，保障控股子公司宁波双成药业有限公 司（以下简称"宁波双成"）资金筹措，推动其业务发展，同时，公司控股股东海 南双成投资有限公司提供相同额度的担保，担保风险可控。本次对外担保的决策 程序符合公司内 ...